Cargando…

P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL

Detalles Bibliográficos
Autores principales:	Strati, P., Coleman, M., Stevens, D., Ma, S., Patti, C., Levy, M., Lossos, I. S., Ramakrishnan Geethakumari, P., Lam, S., Calvo, R., Higgins, K., Budde, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429229/ http://dx.doi.org/10.1097/01.HS9.0000847384.23751.21

Ejemplares similares

A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
por: Strati, Paolo, et al.
Publicado: (2022)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
por: Opat, S., et al.
Publicado: (2022)

P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL
por: Opat, Stephen, et al.
Publicado: (2023)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren’s syndrome patients through immunogenetics
por: Kolijn, P. Martijn, et al.
Publicado: (2023)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
por: Sehn, L. H., et al.
Publicado: (2022)

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
por: Cho, Seok-Goo, et al.
Publicado: (2023)

PReS13-SPK-1129: Biologic therapies in SLE
por: Isenberg, DA
Publicado: (2013)

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
por: Lin, Michael, et al.
Publicado: (2018)

1129. Outpatient Prescribing During the COVID-19 Pandemic
por: Moorthy, Ganga, et al.
Publicado: (2021)

1129. Optimizing Feedback Strategies on the Infectious Diseases Inpatient Service
por: Clark, Eva, et al.
Publicado: (2020)

P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
por: Strati, Paolo, et al.
Publicado: (2023)

1129 Varicella in Belgium: a National One year Prospective Survey
por: Blumental, Sophie, et al.
Publicado: (2014)

1129. Assessment of Nurses’ Views on Antimicrobial Stewardship at a Pediatric Hospital
por: Yu, Diana, et al.
Publicado: (2019)

Postibrutinib relapse outcomes for patients with marginal zone lymphoma
por: Epperla, Narendranath, et al.
Publicado: (2022)

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
por: Hutchings, Martin, et al.
Publicado: (2023)

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
por: Strati, Paolo, et al.
Publicado: (2021)

Epidemiological Investigation of Pediatric Fractures—A Retrospective Cohort Study of 1129 Patients
por: Xiao, Xiaoliang, et al.
Publicado: (2023)

Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States
por: Alderuccio, Juan Pablo, et al.
Publicado: (2021)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

Evaluation of sleep disorder in orthopedic trauma patients: a retrospective analysis of 1129 cases
por: Yang, Hai, et al.
Publicado: (2021)

Biased Use of the IGHV4 Family and Evidence for Antigen Selection in Chlamydophila psittaci-Negative Ocular Adnexal Extranodal Marginal Zone Lymphomas
por: Zhu, Daxing, et al.
Publicado: (2011)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study
por: Annunzio, Kaitlin, et al.
Publicado: (2023)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis
por: Husnain, Muhammad, et al.
Publicado: (2020)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study
por: Epperla, Narendranath, et al.
Publicado: (2023)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
por: Epperla, Narendranath, et al.
Publicado: (2022)

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Byrd, John C., et al.
Publicado: (2023)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_anbofrpvue6vclbq8bgd2ko1ug